Cardiff Oncology (NASDAQ:CRDF) Price Target Raised to $10.00

Cardiff Oncology (NASDAQ:CRDF) had its price objective raised by stock analysts at Piper Sandler from $7.00 to $10.00 in a research report issued on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Piper Sandler’s price objective would suggest a potential upside of 205.81% from the company’s current price.

Other research analysts have also issued reports about the stock. HC Wainwright dropped their price objective on shares of Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating for the company in a research note on Friday, November 8th. Craig Hallum began coverage on shares of Cardiff Oncology in a research note on Friday, September 6th. They set a “buy” rating and a $8.00 price target for the company.

Cardiff Oncology Price Performance

Shares of NASDAQ CRDF opened at $3.27 on Friday. The stock has a market capitalization of $167.20 million, a P/E ratio of -3.48 and a beta of 1.89. Cardiff Oncology has a 1-year low of $1.25 and a 1-year high of $6.42. The business’s 50 day moving average is $2.86 and its two-hundred day moving average is $2.61.

Insider Activity at Cardiff Oncology

In related news, Director Gary W. Pace bought 350,115 shares of Cardiff Oncology stock in a transaction dated Wednesday, December 11th. The shares were acquired at an average cost of $2.60 per share, with a total value of $910,299.00. Following the completion of the transaction, the director now owns 1,047,876 shares in the company, valued at $2,724,477.60. The trade was a 50.18 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 7.80% of the stock is owned by company insiders.

Institutional Trading of Cardiff Oncology

Large investors have recently modified their holdings of the company. Point72 DIFC Ltd purchased a new position in Cardiff Oncology during the 2nd quarter worth $27,000. Ground Swell Capital LLC purchased a new position in shares of Cardiff Oncology during the second quarter valued at $38,000. Dimensional Fund Advisors LP increased its stake in shares of Cardiff Oncology by 34.4% during the second quarter. Dimensional Fund Advisors LP now owns 19,098 shares of the company’s stock valued at $42,000 after buying an additional 4,892 shares during the period. SG Americas Securities LLC bought a new stake in shares of Cardiff Oncology in the third quarter valued at about $64,000. Finally, Invst LLC bought a new position in Cardiff Oncology during the 2nd quarter worth about $74,000. Hedge funds and other institutional investors own 16.29% of the company’s stock.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.